{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ritonavir+100+mg+tablets&page=3",
    "query": {
      "intervention": "Ritonavir 100 mg tablets",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 82,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ritonavir+100+mg+tablets&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ritonavir+100+mg+tablets&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T20:46:03.858Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01563536",
      "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C Infection"
      ],
      "interventions": [
        {
          "name": "ABT-267",
          "type": "DRUG"
        },
        {
          "name": "ABT-450",
          "type": "DRUG"
        },
        {
          "name": "ABT-333",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-02",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-10-07T20:46:03.858Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • Orlando, Florida • Annapolis, Maryland + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Annapolis",
          "state": "Maryland"
        },
        {
          "city": "Poughkeepsie",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01563536"
    },
    {
      "nct_id": "NCT03234036",
      "title": "A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK2838232 100 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "GSK2838232 50 mg capsule",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir 100 mg tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo for GSK2838232 tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-08-02",
      "completion_date": "2017-11-10",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-10-07T20:46:03.858Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03234036"
    },
    {
      "nct_id": "NCT00357604",
      "title": "Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)",
          "type": "DRUG"
        },
        {
          "name": "Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2006-07",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2011-04-08",
      "last_synced_at": "2026-10-07T20:46:03.858Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00357604"
    },
    {
      "nct_id": "NCT00420355",
      "title": "Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "atazanavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 19,
      "start_date": "2007-04",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2009-02-06",
      "last_synced_at": "2026-10-07T20:46:03.858Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00420355"
    },
    {
      "nct_id": "NCT00135343",
      "title": "A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Atazanvir/ritonavir + efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2004-04",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2011-04-14",
      "last_synced_at": "2026-10-07T20:46:03.858Z",
      "location_count": 15,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlantis, Florida + 12 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135343"
    },
    {
      "nct_id": "NCT00245739",
      "title": "TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "TMC-114",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tibotec Pharmaceuticals, Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-04-11",
      "last_synced_at": "2026-10-07T20:46:03.858Z",
      "location_count": 202,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 199 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00245739"
    },
    {
      "nct_id": "NCT02289495",
      "title": "A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK2838232",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-11-18",
      "completion_date": "2015-06-27",
      "has_results": false,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-10-07T20:46:03.858Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02289495"
    },
    {
      "nct_id": "NCT00262522",
      "title": "Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Human Immunodeficiency Virus Infections"
      ],
      "interventions": [
        {
          "name": "lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 664,
      "start_date": "2005-11",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2012-02-06",
      "last_synced_at": "2026-10-07T20:46:03.858Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Fountain Valley, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00262522"
    },
    {
      "nct_id": "NCT01910402",
      "title": "A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir/abacavir/lamivudine FDC",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir/emtricitabine FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 499,
      "start_date": "2013-08-22",
      "completion_date": "2022-08-18",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-10-07T20:46:03.858Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01910402"
    },
    {
      "nct_id": "NCT00414518",
      "title": "Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Tenofovir disoproxil fumarate/Emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir/Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-01",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2013-02-20",
      "last_synced_at": "2026-10-07T20:46:03.858Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • Atlanta, Georgia",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00414518"
    }
  ]
}